eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of safe and effective human-compatible organs to address the global organ shortage, today announced the successful completion of a $100 million Series B financing. The financing was led by Fresenius Medical Care Ventures, with participation from new investors including Leaps by Bayer and Wellington Partners. Existing investors including, but not limited to, ARCH Venture Partners, Biomatics Capital, Alta Partners, and Khosla Ventures all participated.
by eazee-designstudio
